In this issue of The Altascientist, we detail the complexities of central nervous system (CNS) drug development programs. In addition, we share how partnering with an integrated CRO/CDMO can reduce your timelines by up to 40% as your compound advances through each study phase.
Topics covered include: - preclinical safety and toxicity testing
- formulation and manufacturing for nonclinical and clinical studies
- maximizing early phase clinical trials
- bioanalytical considerations
|
Questions? Consult with our experts and tell us how we can support your program.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond. |
